Conditions: Pneumonia
Keywords: Pneumonia Respiratory Infection Infectious Advanced Life Sciences Lung Pulmonary Cethromycin Clarithromycin Biaxin
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 522
Healthy volunteers: no

Brief summary:
The purpose of this study is to compare the efficacy and safety of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia (CAP).

Detailed description:
Lower respiratory tract infections remain one of the leading causes of death worldwide. Increasing rates of antibiotic resistance and newer, more pervasive pneumonia-causative pathogens contribute to this statistic. Currently available macrolide antibiotics for the treatment of community-acquired pneumonia are slowly losing effectiveness, resulting in the need to develop newer drugs to fight resistant infections. In this study, we compare the safety and efficacy of a common macrolide, clarithromycin, to a new ketolide, cethromycin.

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Cethromycin intervention 2: Clarithromycin
Intervention descriptions: intervention 1: Cethromycin 300 mg once per day (QD) for 7 days, administered orally intervention 2: Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally

Protocol document: